IGI Logo

Gland Pharma is currently trading at Rs. 1584.50, up by 7.50 points or 0.48% from its previous closing of Rs. 1577.00 on the BSE.

The scrip opened at Rs. 1577.05 and has touched a high and low of Rs. 1598.80 and Rs. 1566.05 respectively. So far 11868 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 4060.00 on 06-Jan-2022 and a 52 week low of Rs. 1553.80 on 29-Dec-2022.

Last one week high and low of the scrip stood at Rs. 1617.00 and Rs. 1553.80 respectively. The current market cap of the company is Rs. 26054.82 crore.

The promoters holding in the company stood at 57.86%, while Institutions and Non-Institutions held 28.01% and 14.13% respectively.

Gland Pharma has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection at Dundigal Facility in Hyderabad. Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the company’s Dundigal Facility at Hyderabad was conducted from  August 22, 2022 to  August 25, 2022. The company had received 1 observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.